research centers

Search results: Found 1

Listing 1 - 1 of 1
Sort by

The Role of Repaglinide in the Management of Type 2 Diabetes Mellitus

Authors: Abbas M Rahmah --- Majid R Al-Zaidee --- Roaa abbas
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2013 Volume: 12 Issue: 1 Pages: 51-56
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية


ABSTRACT:BACKGROUND :Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas.It achieves this by closing ATP-dependent potassium channels in the membrane of thebeta cells. This depolarizes the beta cells, opening the cells' calcium channels, and theresulting calcium influx induces insulin secretion.OBJECTIVE:To evaluate the effect of repaglinide as a monotherapy or in combination with metformin oncontrolling the fasting plasma glucose, postprandial plasma glucose, HBA1C, and body weight in61 patients with type 2 diabetes mellitus, (DM).PATEINTS & METHODS:During the period between February 2005 and October 2005, the effects of repaglinidehas been reviewed in 61 patients with uncontrolled Type 2 diabetes mellitus (T2DM),they are divided into two groups depending on their previous treatment , the 1st groupincluded 43 of them were on metformin while the remaining 18 patients were on dietonly. Weight, HBA1c, FPG and PPG were checked after 3 and 6 months.RESULTS:It has been found that six months after using Repaglinide in combination with metformin or as amonotherapy cause significant reduction in HBA1c, from 9.8 to 8.1% (P < 0.01) in 1st group, andfrom 7.9 to 6.7%, (P < 0.01) in 2nd group and a significant reduction of FPG from 214.0 mg/dl to148.5 mg/dl (P < 0.01) in 1st group and from 170.7 mg/dl to 130 mg/dl (P < 0.01) in 2nd group.While the PPG shows a decrement from 255.6 mg/dl to 178.8 mg/dl, (P < 0.01) in 1st group andfrom 248.3 mg/dl to166.1 mg/dl (P < 0.01) in 2nd group. There’s no significant weight gain thusmean weight rose from 84.4 Kg to 84.6 Kg, (P > 0.2) in 1st group and from 75.1 kg to 76.1 kg (P >0.2) in 2nd group .CONCLUSION:Repaglinide when used as monotherapy or in combination with metformin improveoverall glycemic control and significantly reduced HBA1c but have no significantchange in body weight


repaglinide --- diabetes --- control.

Listing 1 - 1 of 1
Sort by
Narrow your search

Resource type

article (1)


English (1)

From To Submit

2013 (1)